Ultragenyx Pharmaceutical Inc. (RARE) Cash Flow Statement

The ratio of operating cash flow to net income is consistently positive, but this is largely due to large non-cash add-backs such as stock-based compensation (averaging ~$37M per quarter) and depreciation. However, working capital changes are volatile, swinging from +$54.9M in 2025Q3 to -$56.6M in 2025Q1, which suggests that cash conversion is not stable and may be influenced by timing of collections and payments. Investors should monitor whether these swings reflect underlying business dynamics or one-off items.

While revenue grew 20.1% year-over-year, free cash flow has not improved proportionally; the trailing twelve-month FCF is approximately -$480M, indicating that top-line expansion is not translating into cash generation. The FCF margin, though improved from the trough, is still far from breakeven, and the company's cash balance of $434M suggests a runway of roughly 4-5 quarters at current burn rates, assuming no additional financing. This trajectory implies that the company will need to either accelerate revenue growth, cut costs, or raise capital to sustain operations.

The extremely low capex-to-revenue ratio (0.5% in 2026Q2) indicates that Ultragenyx does not require significant fixed asset investment, consistent with a biotech that outsources manufacturing and relies on partnerships. This means that the primary cash drain is operating expenses, particularly R&D, rather than capital investments. The lack of capex also implies that the company's future growth will depend on successful clinical development and commercialization rather than capacity expansion.

The working capital swings are large relative to the company's scale, with positive contributions in some quarters (e.g., +$54.9M in 2025Q3) and negative in others (e.g., -$56.6M in 2025Q1). This volatility suggests that the company's cash conversion cycle is not stable, possibly due to the lumpy nature of collaboration revenue and milestone payments. Investors should monitor whether these swings are driven by operational efficiency or by one-time items, as they materially affect quarterly cash burn.

The absence of shareholder returns is typical for a development-stage biotech, but it underscores that the company is entirely dependent on external financing to fund its operations. With no dividends or buybacks, the cash flow statement shows that every dollar of cash is either used for operations or held as reserves. The company's capital allocation is focused on advancing its pipeline, but the lack of returns means that investors are relying solely on future appreciation, which is highly uncertain.

The cumulative gap between net income and operating cash flow is about $250M, which is largely attributable to stock-based compensation (over $370M) and depreciation, offset by working capital changes. This suggests that the company's reported losses overstate the actual cash drain, but the cash burn is still substantial. The divergence also implies that the company's earnings quality is low, as a significant portion of expenses are non-cash, but the underlying cash consumption remains a critical concern for liquidity.